Das ist der Hintergrund:
WASHINGTON (dpa-AFX) - Biotechnology company Seagen Inc. (SGEN) and Chinese biopharmaceutical company RemeGen Co., Ltd. on Monday said they have entered into a licensing agreement for RemeGen's disitamab vedotin.
As per the deal, Seagen will make $200 million upfront payment with a potential of up to $2.4 billion on reaching certain regulatory and commercialization targets.
Seagen will have the global rights for development and commercialization of disitamab vedotin, while RemeGen will retain rights for Asia, excluding Japan and Singapore and also entitled to royalty based on net sales of disitamab vedotin in Seagen's territory.
As monotherapy disitamab vedotin has demonstrated antitumor activity in clinical trials in several solid tumor types, including urothelial, gastric and breast cancer, as well as across a spectrum of HER2 expression levels, Seagen said.
https://www.finanznachrichten.de/...alue-up-to-dollar-2-4-bln-020.htm
http://www.remegen.com/ |
Thread abonnieren
